Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing in vitro and preclinical animal mechanisms
PubMed 34368359 · doi:10.1155/2021/9924314
What was done
This narrative review synthesized preclinical in vitro experiments, animal models, and trials of oligonucleotide therapeutics and small-molecule inhibitors evaluating the role of nicotinamide N-methyltransferase (NNMT) in obesity and type 2 diabetes.
What was found
The abstract reports no numerical data or effect sizes. It qualitatively reports that NNMT knockdown or pharmacological inhibition significantly increases energy expenditure, decreases body weight and white adipose mass, improves insulin sensitivity, and normalizes fasting blood glucose and glucose tolerance in preclinical models.
Why it matters
This review outlines NNMT as an emerging therapeutic target for obesity and type 2 diabetes through the modulation of energy expenditure and adipose metabolism.
Limits
The review relies entirely on preclinical in vitro and animal models, with no clinical trials reported in humans. The abstract does not provide quantitative metrics, sample sizes, search strategy details, or the exact molecular mechanisms underlying the observed effects.
Cited by
- context 5-Amino-1MQ produces a thermogenic effect.